BRISTOL, Tenn., March 26 /PRNewswire-FirstCall/ --
To correct any false or misleading impression you may have gained from the news releases, King is providing you with the following clarifying information about EMBEDA.
Serious adverse reactions that may be associated with EMBEDA therapy in clinical use include: respiratory depression, respiratory arrest, apnea, circulatory depression, cardiac arrest, hypotension, and/or shock.
[Full approved indication]
EMBEDA is an extended-release oral formulation of morphine sulfate and naltrexone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
EMBEDA is not indicated for acute/postoperative pain or if the pain is mild or not expected to persist for an extended period of time. EMBEDA is only indicated for postoperative use if the patient is already receiving chronic opioid therapy prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate.
Copyright (C) 2010 King Pharmaceuticals(R), Inc. All rights reserved. EMB7108 03/2010
CONTACT: Investors: Jack Howarth, Vice President, Investor Relations,
+1-908-429-8350
Web site: http://www.embeda.com/